Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VAC-02
- Development stage
- Unknown
- Lead developer
- Minka Therapeutics
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
VAC-02 is a subunit vaccine candidate developed by Minka Therapeutics (formerly InnaVirVax) for the prevention and treatment of HIV-1 infection and other infectious diseases. The vaccine is composed of the W614A-3S peptide, a mutated version of a conserved epitope on the HIV-1 gp41 envelope protein, conjugated to the CRM197 carrier protein. It is designed to induce neutralizing antibodies against the 3S epitope of gp41, which plays a critical role in viral entry and immune evasion. While initially focused on HIV, VAC-02 is positioned as a therapeutic platform with potential applications across a range of infectious diseases. Preclinical studies in animal models have demonstrated its ability to induce specific antibodies when formulated with a squalene emulsion adjuvant, and it has progressed into Phase 1 clinical evaluation.
- Other names
- W614A-3S-CRM197 vaccineW-614A-3S-CRM197 vaccineW 614A-3S-CRM197 vaccine
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on VAC-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VAC-02.